Benzinga··Mohd HaiderBiotech Turnaround: LIMN Stock Rockets 79% on InnocsAI Merger Deal
Liminatus Pharma shares surge 79% after announcing merger with InnocsAI, acquiring oncology pipeline. Stock remains down 97% annually.
LIMNLIMNWclinical-stageafter-hours trading